The role of PPARγ in prostate cancer development and progression

Hartley, A. and Ahmad, I. (2023) The role of PPARγ in prostate cancer development and progression. British Journal of Cancer, 128(6), pp. 940-945. (doi: 10.1038/s41416-022-02096-8) (PMID:36510001) (PMCID:PMC10006070)

[img] Text
286287.pdf - Published Version
Available under License Creative Commons Attribution.



Advanced and metastatic prostate cancer is often incurable, but its dependency on certain molecular alterations may provide the basis for targeted therapies. A growing body of research has demonstrated that peroxisome proliferator-activated receptor gamma (PPARγ) is amplified as prostate cancer progresses. PPARγ has been shown to support prostate cancer growth through its roles in fatty acid synthesis, mitochondrial biogenesis, and co-operating with androgen receptor signalling. Interestingly, splice variants of PPARγ may have differing and contrasting roles. PPARγ itself is a highly druggable target, with agonists having been used for the past two decades in treating diabetes. However, side effects associated with these compounds have currently limited clinical use of these drugs in prostate cancer. Further understanding of PPARγ and novel techniques to target it, may provide therapies for advanced prostate cancer.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Ahmad, Dr Imran and Hartley, Mr Andrew
Authors: Hartley, A., and Ahmad, I.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:British Journal of Cancer
Publisher:Springer Nature
ISSN (Online):1532-1827
Published Online:12 December 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in British Journal of Cancer 128(6): 940-945
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
172068Identification and Validation of New Therapeutic Targets in Enzalutamide-Resistant Prostate CancerImran AhmadCancer Research UK (CRUK)C49745/A19661Institute of Cancer Sciences